The results can serve as a resource for further researches to gain a better understanding of the role of urogenital microbiota in tumor recurrence and identify candidate biomarkers for the application of PD1 or PD-L1 blockers in bladder cancer. This evidence concerns the gene PDCD1 and urinary bladder cancer.